

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/078425 A1

(51) International Patent Classification⁷: **C07D 417/12, A61K 31/505, A61P 3/10**

(74) Common Representative: **DR. REDDY'S LABORATORIES LIMITED**; 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN).

(21) International Application Number: **PCT/IB03/00935**

(22) International Filing Date: **14 March 2003 (14.03.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
180/MAS/2002 15 March 2002 (15.03.2002) IN

(71) Applicant (for all designated States except US): **DR. REDDY'S LABORATORIES LIMITED [IN/IN]**; 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **POTLAPALLY, Rajender, Kumar [IN/IN]**; Custom Chemical Services, Dr. Reddy's Laboratories Limited, Bollaram Road, Miyapur, 500016 Hyderabad, Andhra Pradesh (IN). **SRISILLA, Raju [IN/IN]**; Custom Chemical Services, Dr. Reddy's Laboratories Limited, Bollaram Road, Miyapur, 500016 Hyderabad, Andhra Pradesh (IN). **MAMILLAPALLI, Ramabhadra, Sarma [IN/IN]**; Custom Chemical Services, Dr. Reddy's Laboratories Limited, Bollaram Road, Miyapur, 500016 Hyderabad, Andhra Pradesh (IN). **GADDAM, Om, Reddy [IN/IN]**; Custom Chemical Services, Dr. Reddy's Laboratories Limited, Bollaram Road, Miyapur, 500016 Hyderabad, Andhra Pradesh (IN).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only



Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NOVEL CRYSTALLINE FORM OF 5-[4-[[3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL]METHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE POTASSIUM SALT**

X-ray Crystallogram of Crystalline Form



(57) Abstract: The present invention relates to novel crystalline Form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt having the formula (I). The invention also relates to a pharmaceutical composition comprising the novel crystalline Form and a pharmaceutically acceptable carrier. The novel crystalline Form of the present invention is more active, as an antidiabetic agent than the hitherto known 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt

WO 03/078425 A1